Cornell University scientists announced on Apr. 7 a significant advancement toward developing a safe, reversible, and long-acting nonhormonal male contraceptive. The findings come from a proof-of-principle study in mice that demonstrates how targeting meiosis, the process by which sex cells reproduce, can safely stop sperm production.
The development of an effective male contraceptive has been described as the "holy grail" of contraception research. Currently available options for men are limited to condoms and vasectomies, with the latter being technically reversible but often viewed with caution due to its surgical nature.
The study used JQ1, a small molecule inhibitor initially developed for cancer and inflammatory disease research. While JQ1 is not suitable as a final contraceptive due to neurological side effects, it disrupts prophase 1—a key stage in meiosis—allowing researchers to demonstrate that sperm production can be safely and reversibly halted. "We're practically the only group that's pushing the idea that contraception targets in the testis are a feasible way to stop sperm production," said Paula Cohen, professor of genetics and director of the Cornell Reproductive Sciences Center.
Cohen explained that their approach was designed to avoid harming spermatogonial stem cells—essential for future fertility—and instead focus on halting meiosis without affecting overall health or function. In their experiment, male mice received JQ1 for three weeks and produced no sperm during this period. After stopping treatment, normal sperm production resumed within six weeks; subsequent breeding confirmed both fertility restoration and healthy offspring. "Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal," Cohen said.
Looking ahead, Cohen suggested that such a contraceptive could eventually take form as an injection administered every three months or possibly as a patch.
